<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Atypon//DTD Atypon Systems Journal Archiving and Interchange NLM DTD v3.0.6 20130326//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName atypon-archivearticle3.dtd?><?SourceDTD.Version 3.0.6?><?ConverterInfo.XSLTName atyponoasis-oasisns2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cannabis Cannabinoid Res</journal-id><journal-id journal-id-type="iso-abbrev">Cannabis Cannabinoid Res</journal-id><journal-id journal-id-type="publisher-id">can</journal-id><journal-title-group><journal-title>Cannabis and Cannabinoid Research</journal-title></journal-title-group><issn pub-type="epub">2378-8763</issn><publisher><publisher-name>Mary Ann Liebert, Inc., publishers</publisher-name><publisher-loc>140 Huguenot Street, 3rd FloorNew Rochelle, NY 10801USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6308289</article-id><article-id pub-id-type="publisher-id">10.1089/can.2018.0014</article-id><article-id pub-id-type="doi">10.1089/can.2018.0014</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>The Anti-Inflammatory Properties of Terpenoids from <italic>Cannabis</italic></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gallily</surname><given-names>Ruth</given-names></name><xref ref-type="aff" rid="aff1"><sup>1,</sup></xref><xref ref-type="corresp" rid="corr1"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yekhtin</surname><given-names>Zhannah</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hanu&#x00161;</surname><given-names>Lum&#x000ed;r Ond&#x00159;ej</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><aff id="aff1"><label><sup>1</sup></label>The Lautenberg Center for General and Tumor Immunology, The Hadassah Medical School, The Hebrew University of Jerusalem, Jerusalem, Israel.</aff><aff id="aff2"><label><sup>2</sup></label>Department of Medicinal and Natural Products, Institute for Drug Research, The Hadassah Medical School, The Hebrew University of Jerusalem, Jerusalem, Israel.</aff></contrib-group><author-notes><corresp id="corr1"><label><sup>*</sup></label>Address correspondence to: Ruth Gallily, PhD, The Lautenberg Center for General and Tumor Immunology, The Hadassah Medical School, The Hebrew University of Jerusalem, P.O.B. 11272, Jerusalem 9112102, Israel, <email>ruthg@ekmd.huji.ac.il</email></corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>12</month><year>2018</year><!--string-date: December 2018--></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>12</month><year>2018</year><!--string-date: December 2018--></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>3</volume><issue>1</issue><fpage>282</fpage><lpage>290</lpage><permissions><copyright-statement>&#x000a9; Ruth Gallily <italic>et al</italic>. 2018; Published by Mary Ann Liebert, Inc.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>This Open Access article is distributed under the terms of the Creative Commons License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="can.2018.0014.pdf"/><abstract><title>Abstract</title><p><bold>Introduction:</bold> Cannabinoids are well known to have anti-inflammatory effects in mammalians; however, the Cannabis plant also contains other compounds such as terpenoids, whose biological effects have not yet been characterized. The aim of this study was to compare the anti-inflammatory properties of terpenoids with those of cannabidiol (CBD).</p><p><bold>Materials and Methods:</bold> Essential oils prepared from three monoecious nonpsychoactive chemotypes of Cannabis were analyzed for their terpenoid content and subsequently studied pharmacologically for their anti-inflammatory properties <italic>in vitro</italic> and <italic>in vivo</italic>.</p><p><bold>Results:</bold>
<italic>In vitro</italic>, the three essential oils rich in terpenoids partly inhibited reactive oxygen intermediate and nitric oxide radical (NO<sup>&#x02022;</sup>) production in RAW 264.7 stimulated macrophages. The three terpenoid-rich oils exerted moderate anti-inflammatory activities in an <italic>in vivo</italic> anti-inflammatory model without affecting tumor necrosis factor alpha (TNF&#x003b1;) serum levels.</p><p><bold>Conclusions:</bold> The different Cannabis chemotypes showed distinct compositions of terpenoids. The terpenoid-rich essential oils exert anti-inflammatory and antinociceptive activities <italic>in vitro</italic> and <italic>in vivo</italic>, which vary according to their composition. Their effects seem to act independent of TNF&#x003b1;. None of the essential oils was as effective as purified CBD. In contrast to CBD that exerts prolonged immunosuppression and might be used in chronic inflammation, the terpenoids showed only a transient immunosuppression and might thus be used to relieve acute inflammation.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>cannabis</kwd><kwd>terpenoids</kwd><kwd>anti-inflammation</kwd><kwd>antinociceptive</kwd><kwd>CBD</kwd></kwd-group><counts><fig-count count="5"/><table-count count="1"/><ref-count count="25"/><page-count count="9"/></counts></article-meta></front><body><sec sec-type="intro" id="s001"><title>Introduction</title><p>Human beings have used Cannabis or Cannabis products in various forms for thousands of years<sup><xref rid="B1" ref-type="bibr">1</xref></sup> and references to therapeutic use of the plant are found in Hieratic script on papyri dated around 1700 BC.<sup><xref rid="B2" ref-type="bibr">2</xref></sup> More recent reports have reviewed the history and characteristics of the materials<sup><xref rid="B3" ref-type="bibr">3</xref></sup> and determined their clinical and biological properties.<sup><xref rid="B4" ref-type="bibr">4&#x02013;7</xref></sup> The Cannabis plant contains hundreds of different compounds apart from the major psychoactive compound &#x00394;<sup><xref rid="B9" ref-type="bibr">9</xref></sup>-tetrahydrocannabinol (THC). Some of these are unique to the Cannabis plant,<sup><xref rid="B8" ref-type="bibr">8</xref></sup> while others are shared with other members of the plant kingdom.</p><p>This century has seen a wealth of literature reports on the therapeutic potential of Cannabis and/or its constituents and a comprehensive review conducted by the Committee on the Health Effects of Marijuana: An Evidence Review and Research<sup><xref rid="B9" ref-type="bibr">9</xref></sup> considered more than 10,700 relevant abstracts on this subject. They concluded that there was moderate to conclusive evidence for beneficial effects on chronic pain, and for a variety of other uses in different autoimmune and inflammatory diseases. While studies have focused on THC and the anti-inflammatory effects of the other major constituent, the nonpsychoactive cannabinoid cannabidiol (CBD),<sup><xref rid="B10" ref-type="bibr">10&#x02013;14</xref></sup> the effects of the aromatic terpene constituents have been largely neglected.<sup><xref rid="B15" ref-type="bibr">15</xref></sup> Many of the terpenoids are of pharmacological values.<sup><xref rid="B16" ref-type="bibr">16</xref></sup> About 200 terpenoids have been described in Cannabis and constitute the essential oil of the plant, being responsible for the characteristic odor of the Cannabis.<sup><xref rid="B17" ref-type="bibr">17</xref></sup> The biochemical profiles of the terpenoids in a given plant are more closely associated to the genetics than the environment.<sup><xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B18" ref-type="bibr">18</xref></sup> Physiologically, they are responsible for protecting the plant from predators and attracting pollinating insects among other functions. Pharmacologically, they have been implicated in influencing the properties of the cannabinoids, possibly by a so-called entourage effect.<sup><xref rid="B19" ref-type="bibr">19</xref></sup> Effects on anxiety have been noted as well as positive or negative influences on the antibacterial, anti-inflammatory, and sedative properties of Cannabis components.<sup><xref rid="B19" ref-type="bibr">19</xref></sup> However, there is no consensus on the mechanism by which this is achieved and as to whether the terpenoids themselves possess pharmacologically significant properties.</p><p>We have previously demonstrated the ability of a triple assay, measuring swelling, pain, and tumor necrosis factor alpha (TNF&#x003b1;) serum titers, to measure the anti-inflammatory properties of CBD.<sup><xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B21" ref-type="bibr">21</xref></sup> In this study, we used a similar approach to investigate the antioxidant and anti-inflammatory properties of three different preparations of terpenoid-rich essential oils.</p></sec><sec sec-type="materials|methods" id="s002"><title>Materials and Methods</title><sec id="s003"><title>Essential oil samples</title><p>Samples rich in terpenoids were prepared from three monoecious nonpsychoactive chemotypes of hemp (legal in Europe). Tisza is a Hungarian variety, and Felina and Ferimon are chemotypes adapted to the climate in France.</p><p>All three chemotypes of Cannabis were harvested in August/September 2016 in the pre-Alpine region of Slovenia (Upper Savinja Valley), latitude NS 46&#x000b0;20&#x02032; 29.525 and longitude E 14&#x000b0;50&#x02032; 0.777. Samples of essential oil were prepared by steam distillation of female flowers (upper third of the plant).</p></sec><sec id="s004"><title>Terpenoid analysis</title><p>Samples (1&#x02009;&#x003bc;L) of essential oil were analyzed by gas chromatography/mass spectrometry (GC/MS) in a Hewlett Packard G 1800B GCD system with an HP-5971 gas chromatograph, with an electron ionization detector. The software used was GCD Plus ChemStation and the column was an Rtx<sup>&#x000ae;</sup> 5MS Low bleed GC/MS column (30&#x02009;m&#x000d7;0.25&#x02009;mm&#x000d7;0.25&#x02009;&#x003bc;m film thickness). For analysis, the column was kept at 50&#x000b0;C for 4&#x02009;min and then the temperature was programmed from 50&#x000b0;C to 280&#x000b0;C at 8&#x000b0;C/min; inlet 250&#x000b0;C; detector 280&#x000b0;C; splitless injection/purge time 1.0&#x02009;min; initial temperature 100&#x000b0;C; and with initial time 4.0&#x02009;min. The helium flow rate was 1&#x02009;mL/min. Compound constituents were identified by comparison with standards and by the retention times, Kovats indices and by comparison with mass spectra from computerized libraries (HPCH2205, Wiley7N, and FENSC3).<sup><xref rid="B22" ref-type="bibr">22</xref></sup> The terpenoids isolated by steam distillation as essential oil from each of the cannabis chemotypes gave the test samples T1 (Tisza chemotype), T2 (Felina chemotype), and T3 (Ferimon chemotype), whose analgesic and anti-inflammatory properties were characterized <italic>in vitro</italic> and <italic>in vivo</italic>.</p></sec><sec id="s005"><title>Cell culture</title><p>The murine monocyte/macrophage cell line RAW 264.7 (BALB/c) was obtained from the American Type Culture Collection (ATCC, Rockville, MD) and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% fetal calf serum (FCS), 1&#x02009;mM sodium pyruvate and 100&#x02009;&#x003bc;g/L streptomycin, and 100&#x02009;IU/mL penicillin. The cell line is adherent and the cells were passaged by scraping from the culture dish.</p></sec><sec id="s006"><title>Reactive oxygen intermediate production</title><p>For reactive oxygen intermediate (ROI) assay, RAW 264.7 cells were removed from the culture dish by scraping, and were washed and resuspended at 10<sup>6</sup> cells/mL in Hank's balanced salt solution without phenol red. Cells (5&#x000d7;10<sup>5</sup>) were added to a luminometer tube together with various concentrations of the essential oils (5, 10, 20, or 40&#x02009;&#x003bc;g/mL). After 5&#x02009;min, 10&#x02009;&#x003bc;L luminol (Sigma) and 30&#x02009;&#x003bc;L zymosan (Sigma) were added to each tube and the chemiluminescence was measured immediately in a luminometer (Biolumate LB 95; Berhold, Wilbad, Germany). A second set of samples was incubated for 24&#x02009;h with the essential oils before adding luminol and zymosan. All experiments were done in duplicates.</p></sec><sec id="s007"><title>Nitric oxide (NO<sup>&#x02022;</sup>) determination and MTT evaluation of viability</title><p>RAW 264.7 cells were seeded at a density of 1&#x000d7;10<sup>5</sup> cells/well in 24-well plates and incubated overnight at 37&#x000b0;C and 5% CO<sub>2</sub>. On the following day, the medium was changed to fresh DMEM without FCS, containing various concentrations of the essential oils. The cells were then stimulated by the addition of lipopolysaccharide (LPS) to a concentration of 1&#x02009;&#x003bc;g/mL. Cell supernatants (SNs) were harvested after 24&#x02009;h for nitric oxide radical (NO<sup>&#x02022;</sup>) assay by addition of 100&#x02009;&#x003bc;L SN to an equal volume of Griess reagent (1% sulfanilamide, 0.1% naphthalene diamine, and 2% H<sub>3</sub>PO<sub>4</sub>). After 10&#x02009;min of incubation, the resultant color was measured at 550&#x02009;nm. The amount of NO<sup>&#x02022;</sup> produced, and any inhibition by the test materials, was calculated from a standard curve prepared with NaNO<sub>2</sub>.</p><p>The viability of the cells after incubation with the test materials was determined by MTT viability staining. The absorbance was measured at 550&#x02009;nm on a microplate reader.</p></sec><sec id="s008"><title>Animals</title><p>Female Sabra mice (Israel), 7&#x02013;8 weeks old, were maintained in the specific-pathogen-free unit of the Hadassah Medical School, Hebrew University, Jerusalem, Israel. The experimental protocols were approved by the Institutional Animal Care Ethics Committee. The animals were maintained at a constant temperature (20&#x02013;21&#x000b0;C) and a 12-h light/12-h dark cycle, and were provided a standard pellet diet with water <italic>ad libitum</italic>.</p></sec><sec id="s009"><title>Induction and treatment of paw inflammation</title><p>Inflammation was induced by injection of 40&#x02009;&#x003bc;L of a suspension of 1.5% w/v zymosan A (Sigma) in saline into the subplanter surface of the right hind paw of the mice. This was followed immediately by an injection of the sample intraperitoneally (10, 25, or 50&#x02009;mg/kg). For injection, the terpenoids were dissolved in vehicle containing ethanol:Cremophore:saline at a ratio of 1:1:18. CBD was used as a positive control. Paw swelling and pain perception were assessed after 2, 6, and 24&#x02009;h. Blood was collected after 24&#x02009;h for analysis of TNF&#x003b1; serum levels.</p></sec><sec id="s010"><title>Evaluation of edema</title><p>Calibrated calipers were used to measure paw swelling (thickness) 2, 6, and 24&#x02009;h after injection of zymosan.<sup><xref rid="B20" ref-type="bibr">20</xref></sup></p></sec><sec id="s011"><title>Pain assay</title><p>Pain at 2, 6, and 24&#x02009;h after zymosan injection was assessed by the von Frey nociceptive filament assay,<sup><xref rid="B23" ref-type="bibr">23</xref></sup> where 1.4&#x02013;60&#x02009;g filaments, corresponding to 4.17&#x02013;5.88&#x02009;log of force, was used to test the sensitivity of the swollen paw. The untreated hind paw served as a control. The measurements were performed in a quiet room and the animals were handled for 10&#x02009;s before the test. A trained investigator then applied the filament, poking the middle of the hind paw to provoke a flexion reflex, followed by a clear finch response after paw withdrawal. Filaments of increasing size were each applied for about 3&#x02013;4&#x02009;s. The mechanical threshold force in grams was defined as the lowest force required to obtain a paw retraction response.</p></sec><sec id="s012"><title>Measurement of TNF&#x003b1;</title><p>Blood was collected 24&#x02009;h after zymosan injection, and the sera were assayed for TNF&#x003b1; using a mouse TNF&#x003b1; ELISA kit (R&#x00026;D System), according to the manufacturer's instructions.</p></sec><sec id="s013"><title>Statistical analysis</title><p>Statistical calculations used the nonparametric Mann-Whitney <italic>U</italic> test and Wilcoxon signed-rank test. The results are presented as average&#x000b1;standard error.</p></sec></sec><sec sec-type="results" id="s014"><title>Results</title><sec id="s015"><title>The terpenoid content of essential oils from three different Cannabis chemotypes</title><p>The essential oils from each of the three different chemotypes of Cannabis&#x02014;Tisza (T1), Felina (T2), and Ferimon (T3)&#x02014;were analyzed by GC/MS analyses, and up to 50 different compounds were identified (<xref ref-type="fig" rid="f1">Fig. 1</xref> and <xref rid="T1" ref-type="table">Table 1</xref>). The spectra show similarities and differences between the different Cannabis chemotypes. As the amounts of the identified terpenoids were not quantified, the results in <xref rid="T1" ref-type="table">Table 1</xref> are presented as the relative ratio to the main terpene in the sample, which was set to 100.00%.</p><fig id="f1" fig-type="figure" orientation="portrait" position="float"><label><bold>FIG. 1.</bold></label><caption><p>GC/MS spectra of essential oils from three different chemotypes of Cannabis&#x02014;Tisza (T1), Felina (T2), and Ferimon (T3). Each chemotype displays an individual, characteristic profile. The identity of each peak is summarized in <xref rid="T1" ref-type="table">Table 1</xref>. GC/MS, gas chromatography/mass spectrometry.</p></caption><graphic xlink:href="fig-1"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Terpenoid Content in the Three Chemotypes of Cannabis: The Results Are Presented as the Relative Ratio to the Main Terpene in the Sample, Which Was Set to 100.00%</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th align="left">Terpene</th><th align="center">Kovats Index</th><th align="center">Tisza chemotype (T1) %</th><th align="center">Felina chemotype (T2) %</th><th align="center">Ferimon chemotype (T3) %</th></tr></thead><tbody><tr><td align="left">&#x003b1;-Pinene</td><td align="center">5.85</td><td align="center">31.420</td><td align="center">14.007</td><td align="center">19.413</td></tr><tr><td align="left">Camphene</td><td align="center">6.26</td><td align="center">0.640</td><td align="center">&#x02014;</td><td align="center">0.108</td></tr><tr><td align="left">&#x003b2;-Pinene</td><td align="center">7.04</td><td align="center">20.461</td><td align="center">13.434</td><td align="center">10.153</td></tr><tr><td align="left">Myrcene</td><td align="center">7.43</td><td align="center">100.000</td><td align="center">100.000</td><td align="center">52.755</td></tr><tr><td align="left">&#x003b1;-Phellandrene</td><td align="center">7.85</td><td align="center">1.316</td><td align="center">2.693</td><td align="center">1.163</td></tr><tr><td align="left">&#x00394;<sup><xref ref-type="bibr" rid="B3">3</xref></sup>-Carene</td><td align="center">8.10</td><td align="center">13.020</td><td align="center">2.240</td><td align="center">2.103</td></tr><tr><td align="left">&#x003b1;-Terpinene</td><td align="center">8.30</td><td align="center">1.094</td><td align="center">2.376</td><td align="center">1.018</td></tr><tr><td align="left"><italic>o</italic>-Cymene</td><td align="center">8.59</td><td align="center">&#x02014;</td><td align="center">0.221</td><td align="center">0.564</td></tr><tr><td align="left"><italic>p</italic>-Cymene</td><td align="center">8.53</td><td align="center">0.105</td><td align="center">0.396</td><td align="center">&#x02014;</td></tr><tr><td align="left">Limonene</td><td align="center">8.69</td><td align="center">10.482</td><td align="center">3.379</td><td align="center">7.142</td></tr><tr><td align="left">&#x003b2;-Phellandrene</td><td align="center">8.70</td><td align="center">3.537</td><td align="center">6.794</td><td align="center">2.668</td></tr><tr><td align="left"><italic>cis</italic>-&#x003b2;-Ocimene</td><td align="center">8.96</td><td align="center">4.043</td><td align="center">4.005</td><td align="center">2.520</td></tr><tr><td align="left"><italic>trans</italic>-&#x003b2;-Ocimene</td><td align="center">9.42</td><td align="center">51.700</td><td align="center">39.864</td><td align="center">32.634</td></tr><tr><td align="left">&#x003b3;-Terpinene</td><td align="center">9.78</td><td align="center">1.151</td><td align="center">2.041</td><td align="center">0.880</td></tr><tr><td align="left">Terpinolene</td><td align="center">10.98</td><td align="center">32.842</td><td align="center">81.256</td><td align="center">38.728</td></tr><tr><td align="left">Linalool</td><td align="center">11.32</td><td align="center">0.905</td><td align="center">&#x02014;</td><td align="center">&#x02014;</td></tr><tr><td align="left">1,3,8-<italic>para</italic>-Menthatriene</td><td align="center">11.86</td><td align="center">&#x02014;</td><td align="center">0.449</td><td align="center">0.377</td></tr><tr><td align="left"><italic>endo</italic>-Fenchol</td><td align="center">12.10</td><td align="center">0.263</td><td align="center">&#x02014;</td><td align="center">&#x02014;</td></tr><tr><td align="left"><italic>allo</italic>-Ocimene</td><td align="center">12.70</td><td align="center">1.517</td><td align="center">1.918</td><td align="center">1.179</td></tr><tr><td align="left">Terpinen-4-ol</td><td align="center">14.66</td><td align="center">0.294</td><td align="center">0.665</td><td align="center">&#x000a0;</td></tr><tr><td align="left"><italic>p</italic>-Cymen-8-ol</td><td align="center">14.91</td><td align="center">&#x02014;</td><td align="center">0.421</td><td align="center">&#x000a0;</td></tr><tr><td align="left">Hexyl butanoate</td><td align="center">15.40</td><td align="center">&#x02014;</td><td align="center">0.362</td><td align="center">&#x000a0;</td></tr><tr><td align="left">&#x003b1;-Terpineol</td><td align="center">15.21</td><td align="center">0.303</td><td align="center">0.466</td><td align="center">&#x000a0;</td></tr><tr><td align="left">Eugenol</td><td align="center">22.70</td><td align="center">&#x02014;</td><td align="center">&#x02014;</td><td align="center">1.199</td></tr><tr><td align="left">&#x003b1;-Ylangene</td><td align="center">23.43</td><td align="center">0.191</td><td align="center">0.148</td><td align="center">0.205</td></tr><tr><td align="left">&#x003b1;-Copaene</td><td align="center">23.49</td><td align="center">&#x02014;</td><td align="center">0.144</td><td align="center">0.204</td></tr><tr><td align="left">Hexyl hexanoate</td><td align="center">23.83</td><td align="center">&#x02014;</td><td align="center">0.411</td><td align="center">&#x02014;</td></tr><tr><td align="left">7-<italic>epi</italic>-Sesquithujene</td><td align="center">24.19</td><td align="center">&#x02014;</td><td align="center">0.288</td><td align="center">0.222</td></tr><tr><td align="left">Sesquithujene</td><td align="center">24.84</td><td align="center">&#x02014;</td><td align="center">0.231</td><td align="center">&#x02014;</td></tr><tr><td align="left"><italic>cis</italic>-Caryophyllene</td><td align="center">24.95</td><td align="center">1.778</td><td align="center">1.669</td><td align="center">2.072</td></tr><tr><td align="left"><italic>cis</italic>-&#x003b1;-Bergamotene</td><td align="center">25.10</td><td align="center">0.148</td><td align="center">1.517</td><td align="center">0.846</td></tr><tr><td align="left"><italic>trans</italic>-Caryophyllene</td><td align="center">25.36</td><td align="center">75.569</td><td align="center">68.099</td><td align="center">100.000</td></tr><tr><td align="left"><italic>trans</italic>-&#x003b1;-Bergamotene</td><td align="center">25.99</td><td align="center">3.578</td><td align="center">11.867</td><td align="center">11.100</td></tr><tr><td align="left">&#x003b1;-Guaiene</td><td align="center">26.20</td><td align="center">0.387</td><td align="center">&#x02014;</td><td align="center">&#x02014;</td></tr><tr><td align="left"><italic>trans</italic>-&#x003b2;-Farnesene</td><td align="center">26.92</td><td align="center">3.157</td><td align="center">14.176</td><td align="center">11.811</td></tr><tr><td align="left">&#x003b1;-Humulene</td><td align="center">26.82</td><td align="center">28.338</td><td align="center">25.453</td><td align="center">33.158</td></tr><tr><td align="left"><italic>allo</italic>-Aromadendrene</td><td align="center">27.07</td><td align="center">1.744</td><td align="center">3.130</td><td align="center">&#x02014;</td></tr><tr><td align="left"><italic>ar</italic>-Curcumene</td><td align="center">27.96</td><td align="center">&#x02014;</td><td align="center">0.310</td><td align="center">0.323</td></tr><tr><td align="left">&#x003b2;-Selinene</td><td align="center">28.37</td><td align="center">4.745</td><td align="center">6.653</td><td align="center">6.007</td></tr><tr><td align="left">&#x003b1;-Selinene</td><td align="center">28.74</td><td align="center">3.785</td><td align="center">4.654</td><td align="center">4.747</td></tr><tr><td align="left"><italic>cis</italic>-&#x003b1;-Bisabolene</td><td align="center">29.09</td><td align="center">&#x02014;</td><td align="center">&#x02014;</td><td align="center">1.719</td></tr><tr><td align="left"><italic>trans</italic>-&#x003b1;-Bisabolene</td><td align="center">&#x000a0;</td><td align="center">1.524</td><td align="center">&#x02014;</td><td align="center">&#x02014;</td></tr><tr><td align="left">&#x003b4;-Cadinene</td><td align="center">29.72</td><td align="center">&#x02014;</td><td align="center">0.621</td><td align="center">&#x02014;</td></tr><tr><td align="left">&#x003b2;-Sesquiphellandrene</td><td align="center">29.70</td><td align="center">&#x02014;</td><td align="center">2.011</td><td align="center">&#x02014;</td></tr><tr><td align="left">Selina-3,7(11)-diene</td><td align="center">30.66</td><td align="center">2.343</td><td align="center">2.577</td><td align="center">2.813</td></tr><tr><td align="left">Caryophyllene oxide</td><td align="center">32.16</td><td align="center">4.437</td><td align="center">5.523</td><td align="center">&#x02014;</td></tr><tr><td align="left">Humulene epoxide II</td><td align="center">33.20</td><td align="center">1.151</td><td align="center">1.176</td><td align="center">&#x02014;</td></tr><tr><td align="left"><italic>allo</italic>-Aromadendrene epoxide</td><td align="center">34.42</td><td align="center">&#x000a0;</td><td align="center">0.426</td><td align="center">&#x02014;</td></tr><tr><td align="left">&#x003b1;-Bisabolol</td><td align="center">36.17</td><td align="center">&#x000a0;</td><td align="center">0.226</td><td align="center">&#x02014;</td></tr></tbody></table></table-wrap></sec><sec id="s016"><title><italic>In vitro</italic> studies</title><sec id="s017"><title>Suppression of ROI and NO<sup>&#x02022;</sup> production by RAW macrophages incubated with the terpenoid-rich essential oils</title><p>To study the effects of terpenoids on essential macrophage functions, the RAW 264.7 macrophage cell line was either untreated or incubated with the essential oils at indicated concentrations, before stimulation with zymosan to induce ROIs or LPS to induce NO<sup>&#x02022;</sup> production. The ROI production was measured by luminol chemiluminescence, while NO<sup>&#x02022;</sup> production was measured by resulting nitrite concentration in the supernatant. The generation of ROI by RAW 264.7 macrophages was significantly suppressed following a short 5&#x02009;min-incubation with 40&#x02009;&#x003bc;g/mL terpenoids from chemotypes T1 and T2 (<xref ref-type="fig" rid="f2">Fig. 2</xref>), while lower concentrations had barely any effect. T3 terpenoids, however, showed only a moderate inhibition at 40&#x02009;&#x003bc;g/mL (<xref ref-type="fig" rid="f2">Fig. 2</xref>). When the macrophages were incubated with terpenoids for 24&#x02009;h before zymosan induction of ROI, the terpenoids had barely any inhibitory effect (<xref ref-type="fig" rid="f2">Fig. 2</xref>). This observation suggests for a transient inhibitory effect of terpenoids.</p><fig id="f2" fig-type="figure" orientation="portrait" position="float"><label><bold>FIG. 2.</bold></label><caption><p>Zymosan-induced generation of ROIs by RAW 264.7 macrophages was inhibited by essential Cannabis oils from each of the three chemotypes Tisza (T1), Felina (T2), and Ferimon (T3). RAW 264.7 macrophages (5&#x000d7;10<sup>5</sup>/500&#x02009;&#x003bc;L HBSS) were either untreated (Control) or incubated with 20 or 40&#x02009;&#x003bc;L essential oils for 5&#x02009;min or 24&#x02009;h before ROI induction by zymosan. The ROI was measured by luminol chemiluminescence. The percentage inhibition of ROI production is presented. *<italic>p</italic>&#x0003c;0.05. ROI, reactive oxygen intermediate; HBSS, Hank's Balanced Salt Solution.</p></caption><graphic xlink:href="fig-2"/></fig><p>Similar to ROI inhibition, the T1 and T2 essential oils significantly suppressed LPS-induced NO<sup>&#x02022;</sup> production by RAW macrophages when applied at a concentration of 40&#x02009;&#x003bc;g/mL (<xref ref-type="fig" rid="f3">Fig. 3</xref>). Lower concentrations of T1 and T2 had almost no effect. The T3 essential oil had barely any effect at the concentrations used.</p><fig id="f3" fig-type="figure" orientation="portrait" position="float"><label><bold>FIG. 3.</bold></label><caption><p>LPS-induced generation of NO<sup>&#x02022;</sup> by RAW 264.7 macrophages was inhibited by essential Cannabis oils from each of the three chemotypes Tisza (T1), Felina (T2), and Ferimon (T3). RAW 264.7 macrophages were incubated in serum-free medium alone or in the presence of various amounts of the essential oils, as indicated in the figure. After 5&#x02009;min, the macrophages were exposed to LPS (1&#x02009;&#x003bc;g/mL) for 24&#x02009;h and the nitrite concentration in the supernatant reflecting NO<sup>&#x02022;</sup> production was measured using the Griess reagent. *<italic>p</italic>&#x0003c;0.05, **<italic>p</italic>&#x0003c;0.01. LPS, lipopolysaccharide.</p></caption><graphic xlink:href="fig-3"/></fig><p>The MTT assay showed that the inhibition of NO<sup>&#x02022;</sup> and ROI by terpenoids was not due to cytotoxicity, since all the cells remained over 80% viable with all concentrations tested (data not shown).</p></sec></sec><sec id="s018"><title><italic>In vivo</italic> studies</title><sec id="s019"><title>Anti-inflammatory and antinociceptive effects of terpenoid-rich essential oils</title><p>In this study, we used the well-accepted mouse model of zymosan-induced inflammation to investigate the anti-inflammatory and antinociceptive activities of the three terpenoid preparations. The extent of hind paw swelling was determined 2, 6, and 24&#x02009;h following paw injection of 60&#x02009;&#x003bc;g zymosan alone (control) or together with intraperitoneal injection of various concentrations of essential oils from each of the three chemotypes Tisza (T1), Felina (T2), and Ferimon (T3). For comparison, a mouse group was treated with CBD (5&#x02009;mg/kg), which is well known to exert anti-inflammatory and antinociceptive effects.<sup><xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B21" ref-type="bibr">21</xref></sup> Intraperitoneal injection of each of the three terpenoid preparations significantly reduced zymosan-induced paw swelling at all three concentrations tested (10, 25, and 50&#x02009;mg/kg) (<xref ref-type="fig" rid="f4">Fig. 4A</xref>). There were no significant differences between the three concentrations, meaning that a plateau effect has been reached and no further inhibition can be achieved by increasing the dose. Also, it should be noted that the three terpenoids were less potent than CBD.</p><fig id="f4" fig-type="figure" orientation="portrait" position="float"><label><bold>FIG. 4.</bold></label><caption><p>Anti-inflammatory <bold>(A)</bold> and antinociceptive <bold>(B)</bold> effects of intraperitoneally injected CBD or essential oils from each of the three Cannabis chemotypes Tisza (T1), Felina (T2), and Ferimon (T3). <bold>(A)</bold> Prevention of zymosan-induced swelling of hind paw; 1.5% zymosan in 40&#x02009;&#x003bc;L was injected into the subplanter surface of the right hind paw. Immediately thereafter, CBD (5&#x02009;mg/kg) or essential oils (10, 25, or 50&#x02009;mg/kg) dissolved in vehicle containing ethanol:Cremophore:saline at a ratio of 1:1:18 was injected intraperitoneally. The paw thickness indicative for paw swelling was measured 2, 6, and 24&#x02009;h thereafter. The paw thickness of untreated mice was 2.3&#x02009;mm, which made the baseline of the graph. <italic>N</italic>=9 in each treatment group. *<italic>p</italic>&#x0003c;0.05, **<italic>p</italic>&#x0003c;0.01. <bold>(B)</bold> The hyperalgesia occurring after zymosan injection in control and treated mice as described in <bold>(A)</bold> was measured by using the von Frey nociceptive filament assay. The higher the paw withdrawal threshold, the higher is the antinociceptive effect of the drug. <italic>N</italic>=9 in each treatment group. *<italic>p</italic>&#x0003c;0.05, **<italic>p</italic>&#x0003c;0.01. CBD, cannabidiol.</p></caption><graphic xlink:href="fig-4"/></fig><p>Next, we studied the antinociceptive effects of the three terpenoid preparations in comparison to CBD. To this end, the same mice described above for zymosan-induced paw swelling were used to determine the paw withdrawal threshold by applying von Frey filaments on the paws. Higher paw withdrawal threshold is indicative for better pain-relieving effects. As expected, CBD significantly increased the paw withdrawal threshold (<xref ref-type="fig" rid="f4">Fig. 4B</xref>). Also, the T1 terpenoids at 25 and 50&#x02009;mg/kg could significantly increase the pain threshold (<xref ref-type="fig" rid="f4">Fig. 4B</xref>), although less potent than CBD. T1 showed a correlative dose&#x02013;response at 6&#x02009;h, while no significant difference between the three dose groups could be observed at 2 and 24&#x02009;h (<xref ref-type="fig" rid="f4">Fig. 4B</xref>).</p><p>In contrast, only a moderate pain inhibition could be achieved with the T2 and T3 terpenoid preparations (<xref ref-type="fig" rid="f4">Fig. 4B</xref>). No correlative dose&#x02013;response could be seen for T2 and T3, suggesting for having reached a maximum effect. The more potent pain-relieving effects of T1 in comparison to T2 and T3 is correlative to the better prevention of paw swelling by T1 (compare <xref ref-type="fig" rid="f4">Fig. 4B</xref> with 4A). Of note, the antinociceptive effects of all compounds, including CBD, were most prominent at 6&#x02009;h.</p></sec><sec id="s020"><title>TNF&#x003b1; serum titer</title><p>TNF&#x003b1; is one of the proinflammatory cytokines that is produced during inflammation and activates the nociceptive terminals that innervate the inflamed tissue.<sup><xref rid="B24" ref-type="bibr">24</xref></sup> It was therefore important to study the effect of terpenoids on TNF&#x003b1; serum levels. However, none of the terpenoid preparations had any significant effect on the TNF&#x003b1; serum level 24&#x02009;h after zymosan injection (<xref ref-type="fig" rid="f5">Fig. 5</xref>). Under the same conditions, CBD reduced the level of TNF&#x003b1; significantly by about 48% (<xref ref-type="fig" rid="f5">Fig. 5</xref>).</p><fig id="f5" fig-type="figure" orientation="portrait" position="float"><label><bold>FIG. 5.</bold></label><caption><p>TNF&#x003b1; in the sera of mice treated with zymosan and essential oils. Twenty-four hours after injecting zymosan and/or an intraperitoneal dose of CBD (5&#x02009;mg/kg) or essential oils (10, 25, or 50&#x02009;mg/kg) dissolved in vehicle containing ethanol:Cremophore:saline at a ratio of 1:1:18, the TNF&#x003b1; concentration in the serum was determined by ELISA. <italic>N</italic>=3 for each treatment group. **<italic>p</italic>&#x0003c;0.01. TNF&#x003b1;, tumor necrosis factor alpha.</p></caption><graphic xlink:href="fig-5"/></fig></sec></sec></sec><sec sec-type="discussion" id="s021"><title>Discussion</title><p>The terpenoids provide the cannabis plant with its characteristic fragrance and it is generally accepted that they provide protection from marauding insects. Although more than 230 different named terpenoids have been identified, in Cannabis, only about 50 known terpenoids have been identified in a single plant sample, and the profile may be characteristic of a given chemotype (Hanu&#x00161; LO, unpublished data). This variety is reflected in the differences noted between the three cannabis chemotypes used in this study. Despite suggestions that differences in the pharmaceutical properties of different chemotypes may be a consequence of the variety of terpenoids present, there is almost no information about the biological and medical properties of cannabis-derived terpenoids.</p><p>We have previously developed a triple assay to demonstrate the anti-inflammatory and antinociceptive properties of CBD.<sup><xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B21" ref-type="bibr">21</xref></sup> This assay measures the ability of any compound to inhibit zymosan-induced paw swelling and to relieve zymosan-induced pain. In addition, by collecting blood 24&#x02009;h after zymosan injection, the assay enables us to determine the effects of the compounds on zymosan-induced TNF&#x003b1; production. We adapted this method to study the anti-inflammatory properties of terpenoid-rich essential oils from three different chemotypes of Cannabis.</p><p>Our data show that the three essential oils, which contain various ratios of 48 identified terpenoids, show moderate anti-inflammatory properties in an induced paw swelling model in mice. All three preparations were much less potent than CBD. Also, no correlative dose&#x02013;response was observed, suggesting that a maximum effect was observed already with the lower dose. T2 was somewhat less potent than T1 and T3 with regard to their paw swelling inhibitory effects. T1, but not T2 and T3, exhibited moderate antipain effects, but still, T1 was less potent than CBD. The differences between terpenoids and CBD might be explained by their different effect on TNF&#x003b1; production. While CBD strongly reduces TNF&#x003b1; production <italic>in vivo</italic>, the terpenoids barely had any effect. <italic>In vitro</italic>, the terpenoids only affected macrophage functions such as ROI and NO<sup>&#x02022;</sup> production at high concentration (40&#x02009;&#x003bc;g/mL), which is in contrast to 6&#x02009;&#x003bc;g/mL CBD required to inhibit 90% of granulocyte-induced ROI production<sup><xref rid="B25" ref-type="bibr">25</xref></sup> and 8&#x02009;&#x003bc;g/mL CBD to inhibit 50% of zymosan-induced ROI in RAW 264.7 macrophages.<sup><xref rid="B21" ref-type="bibr">21</xref></sup></p><p>The effects were chemotype specific to a certain extent, which is in agreement with the individuality of the essential oils with terpenoids. Interestingly, in contrast to CBD, none of the chemotype essential oil had any effect on the levels of zymosan-induced TNF&#x003b1;. This might suggest the terpenoids exert their anti-inflammatory effects through a mechanism other than that employed by the cannabinoids.</p></sec><sec sec-type="conclusions" id="s022"><title>Conclusions</title><p>Different chemotypes of cannabis have a distinctive composition of terpenoids. These essential oils do have anti-inflammatory and antinociceptive activities that vary according to their composition, but they had no effect on TNF&#x003b1; titers. None of the essential oils was as effective as CBD. We suggest that terpenoids may be used to diminute acute inflammation effect, whereas the cannabinoids to inhibit chronic inflammation symptoms.</p></sec></body><back><ack><title>Acknowledgment</title><p>The authors would like to thank Dr. Ronit Sionov for her valuable editorial assistance.</p></ack><sec id="s023" sec-type="COI-statement"><title>Author Disclosure Statement</title><p>The authors declare no conflicts of interest.</p></sec><ref-list content-type="parsed"><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Abel</surname><given-names>EL</given-names></name></person-group>
<source>Marihuana the first twelve thousand years</source>. <publisher-name>McGraw-Hill</publisher-name>: <publisher-loc>New York</publisher-loc>, <year>1982</year>, <fpage>289</fpage> pages</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Russo</surname><given-names>EB</given-names></name></person-group>
<article-title>History of cannabis and its preparations in saga, science, and sobriquet</article-title>. <source>Chem Biodivers</source>. <year>2007</year>;<volume>4</volume>:<fpage>1614</fpage>&#x02013;<lpage>1648</lpage><pub-id pub-id-type="pmid">17712811</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mechoulam</surname><given-names>R</given-names></name></person-group>
<article-title>Cannabis&#x02014;a valuable drug that deserves better treatment</article-title>. <source>Mayo Clin Proc</source>. <year>2012</year>;<volume>87</volume>:<fpage>107</fpage>&#x02013;<lpage>109</lpage><pub-id pub-id-type="pmid">22305022</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Brenneisen</surname><given-names>R</given-names></name></person-group>
<article-title>Chemistry and analysis of phytocannabinoids and other cannabis constituents</article-title>. In: <person-group person-group-type="editor"><name><surname>ElSohly</surname><given-names>MA</given-names></name></person-group> (ed.). <source>Marijuana and the cannabinoids</source>. <publisher-name>Humana Press</publisher-name>: <publisher-loc>Totowa, NJ</publisher-loc>, <year>2007</year>, pp. <fpage>17</fpage>&#x02013;<lpage>49</lpage></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Thoma</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>ElSohly</surname><given-names>M</given-names></name></person-group>
<article-title>Biosynthesis and pharmacology of phytocannabinoids and related chemical constituents</article-title>. In: <source>The Analytical Chemistry of Cannabis</source>. <publisher-name>Elsevier</publisher-name>: <publisher-loc>Amsterdam</publisher-loc>, <year>2015</year>, pp. <fpage>27</fpage>&#x02013;<lpage>41</lpage></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pertwee</surname><given-names>RG</given-names></name></person-group>
<article-title>The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: &#x00394;9-tetrahydrocannabinol, cannabidiol and &#x00394;9-tetrahydrocannabivarin</article-title>. <source>Br J Pharmacol</source>. <year>2008</year>;<volume>153</volume>:<fpage>199</fpage>&#x02013;<lpage>215</lpage><pub-id pub-id-type="pmid">17828291</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Syed</surname><given-names>YY</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>McKeage</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Scott</surname><given-names>LJ</given-names></name></person-group>
<article-title>Delta-9-Tetrahydrocannabinol/cannabidiol (Sativex<sup>&#x000ae;</sup>): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis</article-title>. <source>Drugs</source>. <year>2014</year>;<volume>74</volume>:<fpage>563</fpage>&#x02013;<lpage>578</lpage><pub-id pub-id-type="pmid">24671907</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hanu&#x00161;</surname><given-names>LO</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Meyer</surname><given-names>SM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mu&#x000f1;oz</surname><given-names>E</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Phytocannabinoids: a unified critical inventory</article-title>. <source>Nat Prod Rep</source>. <year>2016</year>;<volume>33</volume>:<fpage>1357</fpage>&#x02013;<lpage>1392</lpage><pub-id pub-id-type="pmid">27722705</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="book">
<collab>The National Academics of Science, Engineering, Medicine</collab>. <article-title>Committee on the Effects of Marijuana: An Evidence Review and Research Agenda</article-title>. <source>The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendation for Research</source>. <publisher-name>The National Academies Press</publisher-name>: <publisher-loc>Washington, DC</publisher-loc>, <year>2017</year></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mechoulam</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Parker</surname><given-names>LA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gallily</surname><given-names>R</given-names></name></person-group>
<article-title>Cannabidiol: an overview of some pharmacological aspects</article-title>. <source>J Clin Pharmacol</source>. <year>2002</year>;<volume>42</volume>(<issue>11 Suppl</issue>):<fpage>11S</fpage>&#x02013;<lpage>19S</lpage><pub-id pub-id-type="pmid">12412831</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Costa</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Colleoni</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Conti</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw</article-title>. <source>Naunyn Schmiedebergs Arch Pharmacol</source>. <year>2004</year>;<volume>369</volume>:<fpage>294</fpage>&#x02013;<lpage>299</lpage><pub-id pub-id-type="pmid">14963641</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nagarkatti</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pandey</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rieder</surname><given-names>SA</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Cannabinoids as novel anti-inflammatory drugs</article-title>. <source>Future Med Chem</source>. <year>2009</year>;<volume>1</volume>:<fpage>1333</fpage>&#x02013;<lpage>1349</lpage><pub-id pub-id-type="pmid">20191092</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ol&#x000e1;h</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>T&#x000f3;th</surname><given-names>BI</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Borb&#x000ed;r&#x000f3;</surname><given-names>I</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes</article-title>. <source>J Clin Invest</source>. <year>2014</year>;<volume>124</volume>:<fpage>3713</fpage>&#x02013;<lpage>3724</lpage><pub-id pub-id-type="pmid">25061872</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Petrosino</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Verde</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Vaia</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Anti-inflammatory properties of cannabidiol, a nonpsychotropic cannabinoid, in experimental allergic contact dermatitis</article-title>. <source>J Pharmacol Exp Ther</source>. <year>2018</year>;<volume>365</volume>:<fpage>652</fpage>&#x02013;<lpage>663</lpage><pub-id pub-id-type="pmid">29632236</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lewis</surname><given-names>MA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Russo</surname><given-names>EB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Smith</surname><given-names>KM</given-names></name></person-group>
<article-title>Pharmacological foundations of cannabis chemovars</article-title>. <source>Planta Med</source>. <year>2018</year>;<volume>84</volume>:<fpage>225</fpage>&#x02013;<lpage>233</lpage><pub-id pub-id-type="pmid">29161743</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Breitmaier</surname><given-names>E</given-names></name></person-group>
<source>Terpenes: flavors, fragrances, pharmaca, pheromones</source>. <publisher-name>Wiley-VCH Verlag GmbH &#x00026; Co. KgaA</publisher-name>: <publisher-loc>Weinheim</publisher-loc>, <year>2006</year>, <fpage>223</fpage> pages</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Russo</surname><given-names>EB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Marcu</surname><given-names>J</given-names></name></person-group>
<article-title>Cannabis pharmacology: the usual suspects and a few promising leads</article-title>. <source>Adv Pharmacol</source>. <year>2017</year>;<volume>80</volume>:<fpage>67</fpage>&#x02013;<lpage>134</lpage><pub-id pub-id-type="pmid">28826544</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Booth</surname><given-names>JK</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Page</surname><given-names>JE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bohlmann</surname><given-names>J</given-names></name></person-group>
<article-title>Terpene synthases from cannabis sativa</article-title>. <source>PLoS One</source>. <year>2017</year>;<volume>12</volume>:<fpage>e0173911</fpage><pub-id pub-id-type="pmid">28355238</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Russo</surname><given-names>EB</given-names></name></person-group>
<article-title>Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects</article-title>. <source>Br J Pharmacol</source>. <year>2011</year>;<volume>163</volume>:<fpage>1344</fpage>&#x02013;<lpage>1364</lpage><pub-id pub-id-type="pmid">21749363</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gallily</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yekhtin</surname><given-names>Z</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hanu&#x00161;</surname><given-names>LO</given-names></name></person-group>
<article-title>Overcoming the bell-shaped dose-response of cannabidiol by using cannabis extract enriched in cannabidiol</article-title>. <source>Pharmacol Pharm</source>. <year>2015</year>;<volume>6</volume>:<fpage>75</fpage>&#x02013;<lpage>85</lpage></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ben-Shabat</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hanu&#x00161;</surname><given-names>LO</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Katzavian</surname><given-names>G</given-names></name>, <etal>et al.</etal></person-group>
<article-title>New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity</article-title>. <source>J Med Chem</source>. <year>2006</year>;<volume>49</volume>:<fpage>1113</fpage>&#x02013;<lpage>1117</lpage><pub-id pub-id-type="pmid">16451075</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Adams</surname><given-names>RP</given-names></name></person-group>
<source>Identification of essential oil components by gas chromatography/mass spectrometry</source>. <publisher-name>Allured Business Media</publisher-name>: <publisher-loc>Carol Stream, IL</publisher-loc>, <year>2007</year>, <fpage>804</fpage> pages</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deuis</surname><given-names>JR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dvorakova</surname><given-names>LS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Vetter</surname><given-names>I</given-names></name></person-group>
<article-title>Methods used to evaluate pain behaviors in rodents</article-title>. <source>Front Mol Neurosci</source>. <year>2017</year>;<volume>10</volume>:<fpage>284</fpage><pub-id pub-id-type="pmid">28932184</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cunha</surname><given-names>TM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Verri</surname><given-names>WA</given-names><suffix> Jr</suffix></name></person-group>, <person-group person-group-type="author"><name><surname>Silva</surname><given-names>JS</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A cascade of cytokines mediates mechanical inflammatory hypernociception in mice</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2005</year>;<volume>102</volume>:<fpage>1755</fpage>&#x02013;<lpage>1760</lpage><pub-id pub-id-type="pmid">15665080</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Malfait</surname><given-names>AM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gallily</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sumariwalla</surname><given-names>PF</given-names></name>, <etal>et al.</etal></person-group>
<article-title>The nonpsychoactive cannabis constituent is an oral anti-arthritic therapeutic in murine collagen-induced arthritis</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2000</year>;<volume>97</volume>:<fpage>9561</fpage>&#x02013;<lpage>9566</lpage><pub-id pub-id-type="pmid">10920191</pub-id></mixed-citation></ref></ref-list><sec id="s024"><title/><boxed-text position="float" orientation="portrait"><p><bold>Cite this article as:</bold> Gallily R, Yekhtin Z, Hanu&#x00161; LO (2018) The anti-inflammatory properties of terpenoids from <italic>Cannabis</italic>, <italic>Cannabis and Cannabinoid Research</italic> 3:1, 282&#x02013;290, DOI: 10.1089/can.2018.0014.</p></boxed-text></sec><glossary><title>Abbreviations Used</title><def-list><def-item><term id="G1">CBD</term><def><p>cannabidiol</p></def></def-item><def-item><term id="G2">DMEM</term><def><p>Dulbecco's modified Eagle's medium</p></def></def-item><def-item><term id="G3">FCS</term><def><p>fetal calf serum</p></def></def-item><def-item><term id="G4">GC/MS</term><def><p>gas chromatography/mass spectrometry</p></def></def-item><def-item><term id="G5">KI</term><def><p>Kovats Index</p></def></def-item><def-item><term id="G6">LPS</term><def><p>lipopolysaccharide</p></def></def-item><def-item><term id="G7">NO</term><def><p>nitric oxide</p></def></def-item><def-item><term id="G8">ROI</term><def><p>reactive oxygen intermediate</p></def></def-item><def-item><term id="G9">SNs</term><def><p>supernatants</p></def></def-item><def-item><term id="G10">THC</term><def><p>tetrahydrocannabinol</p></def></def-item><def-item><term id="G11">TNF&#x003b1;</term><def><p>tumor necrosis factor alpha</p></def></def-item></def-list></glossary></back></article>